The novel non‐steroidal MR antagonist finerenone improves metabolic parameters in high‐fat diet‐fed mice and activates brown adipose tissue via AMPK‐ATGL pathway
Vincenzo Marzolla(Vita-Salute San Raffaele University), Massimiliano Caprio(Vita-Salute San Raffaele University), Maria Rosa Ciriolo(University of Rome Tor Vergata), Carla Boitani(Sapienza University of Rome), Stefania Gorini(Vita-Salute San Raffaele University), Andrea Armani(Vita-Salute San Raffaele University), Peter Kolkhof(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Carmen Marrese(IRCCS Ospedale San Raffaele), Marc Lombès(Université Paris-Sud), Valentina Mularoni(Azienda Sanitaria Unità Locale di Reggio Emilia), Alessandra Feraco(Vita-Salute San Raffaele University), Caterina Mammi(IRCCS Ospedale San Raffaele)
Cited by 69
Related Papers
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2020|2.6k
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis
|European Heart Journal|2021|1.2k
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
|European Heart Journal|2013|573
Cell signalling and the glutathione redox system
|Biochemical Pharmacology|2002|352
Chemotherapeutic Drugs and Mitochondrial Dysfunction: Focus on Doxorubicin, Trastuzumab, and Sunitinib
|Oxidative Medicine and Cellular Longevity|2018|324